title: Incidences of extrapyramidal symptoms in patients with schizophrenia after treatment with long-acting injection (depot) or oral formulations of olanzapine.
abstract: BACKGROUND
  The incidence of extrapyramidal symptoms (EPS) has been shown to be generally low among patients with schizophrenia receiving oral olanzapine. A long-acting injection (LAI) of olanzapine has recently been approved for the treatment of schizophrenia in a number of countries. Accordingly, the objective of the current analyses was to compare the incidences of EPS during treatment with olanzapine LAI versus oral olanzapine.
  
  
  METHODS
  The incidences of treatment-emergent EPS were examined in adults with schizophrenia receiving olanzapine LAI or oral olanzapine for up to 3 years. Short-term data were obtained from two double-blind studies of olanzapine LAI: one included a placebo comparator, and the other included oral olanzapine as an active comparator. Long-term data were obtained from an open-label extension study for olanzapine LAI and from an integrated database for oral olanzapine.
  
  
  RESULTS
  The short-term incidence of EPS was 5.6% during treatment with olanzapine LAI (45-405 mg every 2-4 weeks) and 5.0% with oral olanzapine (5-20 mg/day). Akathisia (2.6% LAI, 1.2% oral), and Parkinson-like symptoms (1.8% LAI, 3.7% oral) were similar between treatment groups. The incidence of EPS for long-term treatment was 9.2% for olanzapine LAI. Incidences of EPS events were not significantly different between patients receiving olanzapine LAI or oral olanzapine for up to 3 years.
  
  
  CONCLUSIONS
  These findings suggest that EPS profiles are similar for olanzapine LAI and oral olanzapine.
authors: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225.
authors: Angela L
authors: AL
authors: Hill
authors: i3 Global, Cary, NC.
authors: Bin
authors: B
authors: Sun
authors: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225.
authors: David P
authors: DP
authors: McDonnell
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D017109:Akathisia, Drug-Induced / Q000209:etiology; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000009:adverse effects*; D003692:Delayed-Action Preparations; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D004421:Dystonia / Q000139:chemically induced; D006801:Humans; D015994:Incidence; D008875:Middle Aged; D000077152:Olanzapine; D020734:Parkinsonian Disorders / Q000139:chemically induced; D012559:Schizophrenia / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D001569:Benzodiazepines; D000077152:Olanzapine
keywords: Drug Therapy; Extrapyramidal Symptoms; Olanzapine; Safety; Schizophrenia; Tolerability